Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Published on Jun 1, 2019in Annals of Surgery10.13
· DOI :10.1097/SLA.0000000000002734
Vincent P. Groot16
Estimated H-index: 16
(JHUSOM: Johns Hopkins University School of Medicine),
Georgios Gemenetzis17
Estimated H-index: 17
(JHUSOM: Johns Hopkins University School of Medicine)
+ 10 AuthorsJin He40
Estimated H-index: 40
Sources
Abstract
Objectives:To establish an evidence-based cut-off to differentiate between early and late recurrence and to compare clinicopathologic risk factors between the two groups.Summary Background Data:A clear definition of “early recurrence” after pancreatic ductal adenocarcinoma resection is currently lac
📖 Papers frequently viewed together
201760.39The Lancet
835 Citations
204 Citations
751 Citations
References42
Newest
#1Lois A. DaamenH-Index: 6
#2Vincent P. Groot (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 16
Last. I. Quintus MolenaarH-Index: 31
view all 6 authors...
Abstract Background Biomarker testing can be helpful to monitor disease progression after resection of pancreatic cancer. This systematic review aims to give an overview of the literature on the diagnostic value of serum tumor markers for the detection of recurrent pancreatic cancer during follow-up. Methods A systematic search was performed to 2 October 2017. All studies reporting on the diagnostic value of postoperatively measured serum biomarkers for the detection of pancreatic cancer recurre...
27 CitationsSource
#1Vincent P. Groot (UU: Utrecht University)H-Index: 16
#2Lois A. Daamen (UU: Utrecht University)H-Index: 6
Last. I. Quintus Molenaar (UU: Utrecht University)H-Index: 31
view all 6 authors...
Abstract Background Controversy exists whether follow-up after resection of pancreatic ductal adenocarcinoma (PDAC) should include standardized imaging for the detection of disease recurrence. The purpose of this study was to evaluate how often patients undergo imaging in a setting where routine imaging is not performed. Secondly, the pattern, timing, and treatment of recurrent PDAC were assessed. Materials and methods This was a post hoc analysis of a prospective database of all consecutive pat...
13 CitationsSource
#1John F. Ryan (Johns Hopkins University)H-Index: 2
#1John F. Ryan (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 3
Last. Joseph M. HermanH-Index: 25
view all 16 authors...
Background A standardized treatment regimen for unresectable isolated local recurrence (ILR) of pancreatic ductal adenocarcinoma has not been established. This study evaluated the outcomes for patients with ILR who underwent stereotactic body radiation therapy (SBRT).
18 CitationsSource
Abstract Background The recent expanding technical possibilities to detect tumor derived mutations in blood, so-called circulating tumor DNA (ctDNA), has rapidly increased the interest in liquid biopsies. This review and meta-analysis explores the clinical value of ctDNA in malignancies of the upper gastro-intestinal tract. Methods PubMed, Cochrane and Embase databases were searched to identify studies reporting the diagnostic, prognostic or predictive value of ctDNA in patients with esophageal,...
34 CitationsSource
#1Paula Ghaneh (University of Liverpool)H-Index: 62
#2Jörg KleeffH-Index: 94
Last. John P. NeoptolemosH-Index: 125
view all 32 authors...
Objective and Background:Local and distant disease recurrence are frequently observed following pancreatic cancer resection, but an improved understanding of resection margin assessment is required to aid tailored therapies.Methods:Analyses were carried out to assess the association between clinical
104 CitationsSource
#1Mashaal Dhir (State University of New York Upstate Medical University)H-Index: 17
#2Gautam K. Malhotra (UNMC: University of Nebraska Medical Center)H-Index: 8
Last. Chandrakanth Are (UNMC: University of Nebraska Medical Center)H-Index: 29
view all 8 authors...
Recent years have seen standardization of the anatomic definitions of pancreatic adenocarcinoma, and increasing utilization of neoadjuvant therapy (NAT). The aim of the current review was to summarize the evidence for NAT in pancreatic adenocarcinoma since 2009, when consensus criteria for resectable (R), borderline resectable (BR), and locally advanced (LA) disease were endorsed. PubMed search was undertaken along with extensive backward search of the references of published articles to identif...
72 CitationsSource
#1Joshua D. Cohen (Johns Hopkins University)H-Index: 16
#2Ammar A. Javed (Johns Hopkins University)H-Index: 23
Last. Anne Marie Lennon (Johns Hopkins University)H-Index: 43
view all 40 authors...
The earlier diagnosis of cancer is one of the keys to reducing cancer deaths in the future. Here we describe our efforts to develop a noninvasive blood test for the detection of pancreatic ductal adenocarcinoma. We combined blood tests for KRAS gene mutations with carefully thresholded protein biomarkers to determine whether the combination of these markers was superior to any single marker. The cohort tested included 221 patients with resectable pancreatic ductal adenocarcinomas and 182 control...
252 CitationsSource
#1Arsen Osipov (Cedars-Sinai Medical Center)H-Index: 7
#2Nicholas N. Nissen (Cedars-Sinai Medical Center)H-Index: 26
Last. Richard Tuli (Cedars-Sinai Medical Center)H-Index: 28
view all 9 authors...
Purpose There is debate regarding the definition and clinical significance of margin clearance in pancreatic ductal adenocarcinoma (PDA). A comprehensive archival analysis of surgical resection margins was performed to determine the effect on locoregional recurrence and survival, and the impact of adjuvant therapy in PDA.
19 CitationsSource
#1Ihsan Ekin Demir (TUM: Technische Universität München)H-Index: 34
#2Carsten Jäger (TUM: Technische Universität München)H-Index: 11
Last. Güralp O. CeyhanH-Index: 41
view all 14 authors...
Objective: The aim of this study was to decipher the true importance of R0 versus R1 resection for survival in pancreatic ductal adenocarcinoma (PDAC). Summary of Background Data: PDAC is characterized by poor survival, even after curative resection. In many studies, R0 versus R1 does not result in different prognosis and does not affect the postoperative management. Methods: Pubmed, Embase, and Cochrane databases were screened for prognostic studies on the association between resection status a...
59 CitationsSource
#1Kyung-Su KimH-Index: 25
#1Kyung Su KimH-Index: 18
Last. Eui Kyu Chie (SNU: Seoul National University)H-Index: 27
view all 4 authors...
PURPOSE: While curative resection is the only chance of cure in pancreatic cancer, controversies exist about the impact of surgical margin status on survival. Non-standardized pathologic report and different criteria on the R1 status made it difficult to implicate adjuvant therapy after resection based on the margin status. We evaluated the influence of resection margins on survival by meta-analysis. MATERIALS AND METHODS: We thoroughly searched electronic databases of PubMed, EMBASE, and Cochra...
49 CitationsSource
Cited By89
Newest
#1Jiawen YaoH-Index: 14
#2Yu Shi (PRC: China Medical University (PRC))H-Index: 2
view all 10 authors...
Abstract null null Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers and carries a dismal prognosis of null null null ∼ null null 10% in five year survival rate. Surgery remains the best option of a potential cure for patients who are evaluated to be eligible for initial resection of PDAC. However, outcomes vary significantly even among the resected patients who were the same cancer stage and received similar treatments. Accurate quantitative preoperative prediction of pr...
Source
#1Ko Tomishima (Juntendo University)H-Index: 2
#2Shigeto Ishii (Juntendo University)H-Index: 2
Last. Wataru Yamagata (Juntendo University)H-Index: 1
view all 0 authors...
A decrease in carbohydrate antigen (CA) 19-9 levels has been proposed as a prognostic marker for survival and recurrence in patients with pancreatic cancer. We evaluated the association between duration of reduced CA 19-9 levels during 6 months after treatment and long-term survival for 79 patients with unresectable locally advanced pancreatic cancer (LAPC). We calculated the differences between pretreatment and monthly CA19-9 levels. We categorized 71 patients with decreases in CA19-9 levels in...
Source
#1Genki Watanabe (JFCR: Japanese Foundation for Cancer Research)H-Index: 2
#2Yuta Ushida (JFCR: Japanese Foundation for Cancer Research)H-Index: 1
Last. Hiromichi Ito (JFCR: Japanese Foundation for Cancer Research)H-Index: 8
view all 0 authors...
BACKGROUND Neoadjuvant therapy is used for borderline resectable pancreatic ductal adenocarcinoma (PDAC) with high risk of incomplete resection and early recurrence. Because distal PDAC is rare, the optimal criteria for neoadjuvant therapy specific for distal PDAC remain unclear. We hypothesized large distal PDAC would recur earlier than small distal PDAC. OBJECTIVE The aim of this study was to identify the risk factors for failure of upfront resection for resectable distal PDAC. METHODS The stu...
1 CitationsSource
Source
#1Marina Affi Koprowski (OHSU: Oregon Health & Science University)H-Index: 1
#2Thomas L. Sutton (OHSU: Oregon Health & Science University)H-Index: 5
Last. Daniel O. Herzig (OHSU: Oregon Health & Science University)H-Index: 21
view all 11 authors...
Background null The definition of early recurrence (ER) in rectal cancer is unclear, and the association of ER with post-recurrence survival (PRS) is poorly described. We therefore sought to identify if time to recurrence (TTR) is associated with PRS. null Methods null We reviewed all curative-intent resections of nonmetastatic rectal cancer from 2003 to 2018 in our institutional registry within an NCI-Designated Comprehensive Cancer Center. Clinicopathologic data at diagnosis and first recurren...
Source
#1Hirotaka Furuke (Kyoto Prefectural University of Medicine)H-Index: 2
#2Tomohiro Arita (Kyoto Prefectural University of Medicine)H-Index: 19
Last. Hisashi Ikoma (Kyoto Prefectural University of Medicine)H-Index: 28
view all 15 authors...
PURPOSE The significance of the duration of the recurrence-free survival after curative resection for colorectal cancer remains unclear. The purpose was to reveal the association between time to recurrence after surgery and the survival after recurrence. METHODS Patients with stage II and III colorectal cancer who underwent curative resection between 2007 and 2015 were retrospectively reviewed (n = 645). Patients with recurrence after surgery (n = 133) were divided into 2 groups: early recurrenc...
Source
#1Giulio BelfioriH-Index: 8
#2Stefano CrippaH-Index: 60
Last. Giuseppe ZamboniH-Index: 81
view all 11 authors...
BACKGROUND Data on long-term actual survival in patients with surgically resected pancreatic ductal adenocarcinoma (PDAC) are limited. The aim of this study was to evaluate the actual 5-year disease-specific survival (DSS) and post-recurrence survival (PRS) in patients who underwent pancreatectomy for PDAC. METHODS Data from patients who underwent upfront surgical resection for PDAC between 2009 and 2014 were analyzed. Exclusion criteria included PDAC arising in the background of an intraductal ...
2 CitationsSource
#1G. Belfiori (UniSR: Vita-Salute San Raffaele University)H-Index: 6
#2Stefano CrippaH-Index: 60
Last. Massimo Falconi (UniSR: Vita-Salute San Raffaele University)H-Index: 105
view all 3 authors...
Source
#1Caroline J. Rieser (University of Pittsburgh)H-Index: 5
#2Heather Jones (University of Pittsburgh)H-Index: 11
Last. James F. Pingpank (University of Pittsburgh)H-Index: 32
view all 12 authors...
INTRODUCTION Early recurrence (ER) is a significant challenge for patients with colorectal peritoneal metastases (CRPM) following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS HIPEC). Preoperative risk stratification for ER would improve preoperative decision making. METHODS We conducted a retrospective study examining patients who underwent CRS HIPEC for CRPM from 2000 to 2018. Optimal definition of ER was determined via minimum p-value approach based on differentiat...
Source
#1Alex B. Blair (Johns Hopkins University)H-Index: 17
#2Lingdi Yin (Johns Hopkins University)H-Index: 5
Last. Jin He (Johns Hopkins University)H-Index: 40
view all 13 authors...
OBJECTIVE: The aim of this study was to characterize the patterns and treatment of disease recurrence in patients achieving a pathological complete response (pCR) following neoadjuvant chemoradiation for advanced pancreatic ductal adenocarcinoma (PDAC). SUMMARY OF BACKGROUND DATA: A pCR is an independent predictor for improved survival in PDAC. However, disease recurrence is still observed in these patients. METHODS: Patients with advanced PDAC who were treated with neoadjuvant therapy and had a...
6 CitationsSource